| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
IC50: 2.4 μM (CDC25A), 3.9 μM (CDC25B2), 6.3 μM (CDC25B3), 5.4 μM (CDC25C), 4.6 μM (CDC25C-cat)[1].
CDC25A (IC50 = 2.4 uM), CDC25B2 (IC50 = 3.9 uM), CDC25B3 (IC50 = 6.3 uM), and CDC25C (IC50 = 5.4 uM). BN82002 hydrochloride is a specific and irreversible pan-inhibitor of the CDC25 phosphatase family. |
|---|---|
| ln Vitro |
BN82002 is tested in vitro on a variety of human tumor cell lines to determine its impact on cell growth. For the control, menadione is utilized, which has been shown to impede the growth of cells. BN82002 and menadione both exhibit concentration-dependent sensitivity in the low micromolar range in all of the tested cell lines. The cell line with the highest sensitivity, MIA PaCa-2, is from pancreatic cancer; its IC50 is 7.2 μM, while HT-29, from colon cancer, has a lower sensitivity of 32.6 ΔM. Comparable to the menadione (5–15 μM) range of action is reported. The results also indicate that 50 μM BN82002 completely suppresses cell division; the distribution of the cell cycle is only slightly altered, with a small reduction in S phase and an increase in cells with both G1 and G2 DNA content, indicating that the treated cells are arrested at different phases of the cell cycle[1].
BN82002 hydrochloride inhibits the phosphatase activity of recombinant human CDC25A, CDC25B, and CDC25C in vitro with low micromolar IC50 values. By blocking CDC25 activity, it prevents the dephosphorylation and activation of cyclin-dependent kinases (CDKs), leading to cell cycle arrest at the G2/M checkpoint. |
| ln Vivo |
In vivo, BN82002 hydrochloride reduces tumor growth in mouse xenograft models. By inducing G2/M cell cycle arrest, it suppresses the proliferation of cancer cells. The irreversible inhibition of CDC25 phosphatases leads to sustained pathway inhibition, making it an effective tool for studying cell cycle regulation and anticancer strategies.
|
| Enzyme Assay |
For non-cellular assays, recombinant human CDC25 phosphatase (A, B, or C) is incubated with a fluorogenic substrate such as 3-O-methylfluorescein phosphate (OMFP) in assay buffer. BN82002 hydrochloride is added at varying concentrations (0.5-100 uM). Fluorescence release is measured (excitation 485 nm, emission 530 nm) to calculate IC50 values for each isoform.
|
| Cell Assay |
For cell-based assays, cancer cell lines (e.g., HeLa, PC-3, or MCF-7) are treated with BN82002 hydrochloride (2-50 uM) for 24-72 hours. Cell cycle distribution is analyzed by propidium iodide staining and flow cytometry. Cell proliferation is assessed by MTT or colony formation assays. CDC2 (CDK1) phosphorylation at Tyr-15 is measured by Western blot using phospho-specific antibodies.
|
| Animal Protocol |
For animal studies, BN82002 hydrochloride is administered intraperitoneally or orally to tumor-bearing mice (e.g., xenograft models). Doses typically range from 10-100 mg/kg given daily or every other day. Tumor volume is measured by calipers. Tumors are harvested for analysis of cell cycle markers (cyclin B1, phospho-CDC2) and apoptosis (cleaved caspase-3). Mouse body weight is monitored for toxicity assessment.
|
| ADME/Pharmacokinetics |
BN82002 hydrochloride is typically dissolved in DMSO for in vitro use. For in vivo administration, it can be formulated in saline or a vehicle containing DMSO, PEG300, and Tween-80. Detailed pharmacokinetic parameters (half-life, Cmax, AUC) have not been extensively reported but are available in the literature from preclinical studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for BN82002 hydrochloride are derived from preclinical studies. At therapeutic doses (e.g., 50 mg/kg in mice), no significant systemic toxicity or body weight loss has been reported. As a cell cycle inhibitor, it may cause reversible myelosuppression at high doses. Standard safety precautions for handling research chemicals should be followed.
|
| References | |
| Additional Infomation |
BN82002 hydrochloride (CAS: 1049740-43-3) has a molecular formula of C17H17ClN2O3·HCl and a molecular weight of 369.24. It is a potent and selective irreversible inhibitor of the CDC25 phosphatase family, making it a valuable tool for studying cell cycle regulation, checkpoint control, and cancer biology. It is not approved for clinical use.
|
| Molecular Formula |
C19H26CLN3O4
|
|---|---|
| Molecular Weight |
395.880444049835
|
| Exact Mass |
395.161
|
| CAS # |
1049740-43-3
|
| Related CAS # |
BN82002;396073-89-5
|
| PubChem CID |
16078950
|
| Appearance |
Brown to orange solid-liquid Mixture
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
435
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)C1=CC(=C(C(=C1)OC)O)CN(C)CCC2=CC=C(C=C2)[N+](=O)[O-].Cl
|
| InChi Key |
FGPZRTQNJSSCAQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H25N3O4.ClH/c1-20(2)17-11-15(19(23)18(12-17)26-4)13-21(3)10-9-14-5-7-16(8-6-14)22(24)25;/h5-8,11-12,23H,9-10,13H2,1-4H3;1H
|
| Chemical Name |
4-(dimethylamino)-2-methoxy-6-[[methyl-[2-(4-nitrophenyl)ethyl]amino]methyl]phenol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 220 mg/mL (555.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5.5 mg/mL (13.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 55.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5.5 mg/mL (13.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 55.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 5.5 mg/mL (13.89 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5260 mL | 12.6301 mL | 25.2602 mL | |
| 5 mM | 0.5052 mL | 2.5260 mL | 5.0520 mL | |
| 10 mM | 0.2526 mL | 1.2630 mL | 2.5260 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
